Ninnion has announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke. It would be the first drug of its kind in the treatment of stroke, potentially making it eligible for Breakthrough Therapy designation by the FDA, a designation that can accelerate the development timeline.
Category Scientific / Research
Published in Yahoo Finance